Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CELLINK in connection with the acquisition of Ginolis
Mandate

Vinge advises CELLINK in connection with the acquisition of Ginolis

February 15, 2021 M&A Capital Markets and Public M&A Intellectual Property

Vinge has advised CELLINK AB (publ) in connection with the acquisition of all shares in Ginolis Oy. Ginolis conducts operations in relation to automated diagnostics and provides advanced robotic solutions to the medical- and diagnostics industries.

The purchase price on a cash and debt free basis amount to EUR 70 million. Forty per cent of the purchase price will be paid with newly issued class B shares in CELLINK, with the remainder in cash.

Vinge’s team mainly consisted of Anders Strid, Johanna Hamrefält (project manager M&A), Anna Maria Lagerqvist Gahm and Alexander Lindeberg (IP), Aleksandar Bajic (M&A), Martin Svanberg (W&I) in addition to Edin Agic (Capital Markets). Krogerus Attorneys acted as local counsel in Finland.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025